Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $16.04, but opened at $17.24. Cullinan Therapeutics shares last traded at $16.2950, with a volume of 225,289 shares changing hands.
Key Cullinan Therapeutics News
Here are the key news stories impacting Cullinan Therapeutics this week:
- Positive Sentiment: HC Wainwright raised multiple EPS forecasts and reiterated its Buy rating. The firm increased its Q3 2026 estimate to a loss of $0.86 per share from $0.90, Q4 2026 to a loss of $0.89 from $0.93, and FY2026 to a loss of $3.45 from $3.53. It also lifted estimates for Q1-Q3 2027 and sharply improved its FY2027 forecast to a loss of $1.81 per share from $3.89. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
- Positive Sentiment: The most notable change was a projected return to quarterly profitability. HC Wainwright now expects CGEM to earn $0.39 per share in Q4 2027, compared with its previous forecast for a $1.00 loss, suggesting improved operating performance and a potentially faster path toward profitability.
- Positive Sentiment: The analyst’s $35 price target implies substantial upside from recent trading levels, reinforcing the view that Cullinan’s drug-development pipeline could create significant long-term value.
- Neutral Sentiment: Despite the upgrades, Cullinan is still expected to report substantial losses through most of 2026 and 2027. The company remains a development-stage biotechnology business, so future results will depend heavily on clinical progress, regulatory milestones and funding needs.
- Negative Sentiment: HC Wainwright’s FY2026 loss estimate of $3.45 per share remains worse than the broader consensus estimate of a $3.08 loss, indicating that near-term earnings expectations are not uniformly favorable.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wedbush raised their target price on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. BTIG Research reiterated a “buy” rating and set a $40.00 price target on shares of Cullinan Therapeutics in a research report on Friday, September 25th. Finally, TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.71.
Cullinan Therapeutics Trading Up 9.4%
The company has a market capitalization of $1.13 billion, a PE ratio of -5.63 and a beta of -0.05. The company has a fifty day simple moving average of $19.50 and a 200-day simple moving average of $16.76.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, equities analysts predict that Cullinan Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.
Insider Transactions at Cullinan Therapeutics
In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the sale, the insider owned 158,844 shares in the company, valued at $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Cullinan Therapeutics
A number of hedge funds have recently modified their holdings of the business. AlphaCentric Advisors LLC boosted its holdings in Cullinan Therapeutics by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company’s stock worth $286,000 after buying an additional 1,094 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Cullinan Therapeutics in the second quarter valued at about $25,000. Allworth Financial LP lifted its position in shares of Cullinan Therapeutics by 152.4% during the 2nd quarter. Allworth Financial LP now owns 2,893 shares of the company’s stock valued at $53,000 after acquiring an additional 1,747 shares during the period. Royal Bank of Canada lifted its position in shares of Cullinan Therapeutics by 160.6% during the 1st quarter. Royal Bank of Canada now owns 4,044 shares of the company’s stock valued at $58,000 after acquiring an additional 2,492 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Cullinan Therapeutics during the 2nd quarter worth approximately $53,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.
Cullinan Therapeutics Company Profile
Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.
Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.
Featured Stories
- Five stocks we like better than Cullinan Therapeutics
- AI Chip Demand Gives Linde a New Growth Catalyst
- Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion
- 3 Sectors Where Volatility Is Creating Entry Points, Not Exit Signals
- D-Wave’s Gate-Model Tech Notches a Major Milestone
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
